Zacks Research Brokers Boost Earnings Estimates for Amgen

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for Amgen in a report released on Tuesday, February 25th. Zacks Research analyst R. Department now expects that the medical research company will earn $5.22 per share for the quarter, up from their previous estimate of $5.03. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. Zacks Research also issued estimates for Amgen’s Q3 2025 earnings at $5.33 EPS, Q4 2025 earnings at $5.44 EPS and FY2025 earnings at $20.16 EPS.

A number of other research firms have also recently issued reports on AMGN. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler increased their price objective on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Deutsche Bank Aktiengesellschaft dropped their target price on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Finally, Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $314.09.

Amgen Trading Down 0.2 %

Shares of NASDAQ AMGN opened at $305.82 on Friday. Amgen has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a market cap of $164.29 billion, a price-to-earnings ratio of 40.51, a P/E/G ratio of 2.63 and a beta of 0.56. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company’s fifty day moving average is $279.97 and its 200-day moving average is $300.24.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Capital World Investors boosted its holdings in shares of Amgen by 1,292.0% in the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock valued at $1,693,042,000 after purchasing an additional 6,029,058 shares in the last quarter. Norges Bank bought a new stake in shares of Amgen during the 4th quarter worth $1,541,991,000. Capital International Investors boosted its stake in Amgen by 40.1% in the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock valued at $3,182,843,000 after buying an additional 3,495,503 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Amgen by 25.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company’s stock worth $3,441,909,000 after acquiring an additional 2,672,975 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Amgen in the fourth quarter worth about $401,913,000. 76.50% of the stock is owned by institutional investors.

Insider Activity at Amgen

In other news, EVP David M. Reese sold 8,711 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the sale, the executive vice president now directly owns 62,147 shares of the company’s stock, valued at approximately $18,222,743.34. This represents a 12.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. Company insiders own 0.69% of the company’s stock.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.11%. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.